Wells Fargo’s Blueprint Medicines BPMC Stock Holding History

Wells Fargo’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-10,000	Closed	-$133K	–	6293
2020 Q1	$133K	Buy	+10,000	New	+$644K	﹤0.01%	4916

Other funds holding BPMC

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Wells Fargo's BPMC Position: Q3 2025 in Review

Wells Fargo sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 35,338 shares — an estimated $4.53M sold.

Wells Fargo first reported a position in BPMC in Q2 2015 and held it in 41 quarters. The position peaked at $9M in Q1 2021. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

Wells Fargo reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
Wells Fargo sold 35,338 Blueprint Medicines shares in Q3 2025, an estimated $4.53M.
Wells Fargo first reported a position in Blueprint Medicines in Q2 2015 and held it in 41 quarters.
Wells Fargo's Blueprint Medicines position peaked at $9M in Q1 2021.
5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on Wells Fargo's 13F filing for Q3 2025, filed 13 Nov 2025.